Ancillary Study to Protocol 20060104

Protein Phosphorylation Ancillary Study to Amgen Protocol 20060104: Open Label Study to Assess the Safety and Immunogenicity of Etanercept SFP When Administered to Subjects Diagnosed With Rheumatoid Arthritis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00439894

Enrollment

Registered

2007-02-26

Start date

2006-12-31

Completion date

2007-10-31

Last updated

2008-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis, etanercept, Enbrel, Amgen

Brief summary

Ancillary study to the Etanercept protocol 20060104. Subjects have been asked to provide additional blood samples for further assessment.

Interventions

PROCEDUREBlood draw

blood draw at baseline, week 12 and week 24

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed informed Consent Meet all inclusion critieria outlined in Amgen Protocol 20060104

Exclusion criteria

* Meet

Design outcomes

Primary

Measure	Time frame
To explore the correlation between pheripheral blood cell protein phosphorylation assessemnts and rheumatoid arthritis disease activity.	week 24

Secondary

Measure	Time frame
Explore the correlations to etanercept clinical response (ACR and DAS scores) may also be explored.	week 24

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026